Use of alpha-blockers and the risk of hip/femur fractures.
OBJECTIVE: To study the association between use of alpha-blockers and risk of hip/femur fractures. DESIGN: Population-based case-control study. SETTING: General Practice Research Database. SUBJECTS: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Con...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2003
|
| _version_ | 1826271561260204032 |
|---|---|
| author | Souverein, P Van Staa, T Egberts, A De la Rosette, J Cooper, C Leufkens, H |
| author_facet | Souverein, P Van Staa, T Egberts, A De la Rosette, J Cooper, C Leufkens, H |
| author_sort | Souverein, P |
| collection | OXFORD |
| description | OBJECTIVE: To study the association between use of alpha-blockers and risk of hip/femur fractures. DESIGN: Population-based case-control study. SETTING: General Practice Research Database. SUBJECTS: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Controls were matched 1 : 1 on gender, year of birth and general practitioner-practice. RESULTS: In all, 4571 cases and an equal number of controls were identified. Current use of alpha-blockers (prazosin, doxazosin, indoramin, terazosin, alfuzosin and tamsulosin) was compared with non-use of alpha-blockers. Current use of alpha-blockers on the index date was associated with an increased risk of hip/femur fracture [adjusted odds ratio (OR) 1.9, 95% confidence interval (CI): 1.1-3.0] in the overall analysis. The effect was particularly strong for first prescriptions within a treatment episode (adjusted OR 5.1, 95% CI: 1.0-31.7) and during the first month of treatment (adjusted OR 4.1, 95% CI: 0.7-23.9). Stratification according to indication of use showed that current use of alpha-blockers was not associated with hip/femur fracture in men with a diagnosis of benign prostatic hyperplasia (adjusted OR 1.0, 95% CI: 0.4-2.5), but was associated in men who used alpha-blockers for cardiovascular disease (adjusted OR 2.8, 95% CI: 1.4-5.4). CONCLUSION: Current use of alpha-blockers was associated with an increased risk of hip/femur fracture and with the start of a new treatment episode. The effect seemed to be confined to patients who used alpha-blockers for cardiovascular disease. Caution with respect to first-dose effects related to the initiation of a new episode of alpha-blocker treatment is advised. |
| first_indexed | 2024-03-06T21:58:35Z |
| format | Journal article |
| id | oxford-uuid:4dccc8df-7b84-453c-af44-3b35a99a4d9e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:58:35Z |
| publishDate | 2003 |
| record_format | dspace |
| spelling | oxford-uuid:4dccc8df-7b84-453c-af44-3b35a99a4d9e2022-03-26T15:57:32ZUse of alpha-blockers and the risk of hip/femur fractures.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4dccc8df-7b84-453c-af44-3b35a99a4d9eEnglishSymplectic Elements at Oxford2003Souverein, PVan Staa, TEgberts, ADe la Rosette, JCooper, CLeufkens, HOBJECTIVE: To study the association between use of alpha-blockers and risk of hip/femur fractures. DESIGN: Population-based case-control study. SETTING: General Practice Research Database. SUBJECTS: Cases were defined as men, aged 40 years and older with a first diagnosis for hip/femur fracture. Controls were matched 1 : 1 on gender, year of birth and general practitioner-practice. RESULTS: In all, 4571 cases and an equal number of controls were identified. Current use of alpha-blockers (prazosin, doxazosin, indoramin, terazosin, alfuzosin and tamsulosin) was compared with non-use of alpha-blockers. Current use of alpha-blockers on the index date was associated with an increased risk of hip/femur fracture [adjusted odds ratio (OR) 1.9, 95% confidence interval (CI): 1.1-3.0] in the overall analysis. The effect was particularly strong for first prescriptions within a treatment episode (adjusted OR 5.1, 95% CI: 1.0-31.7) and during the first month of treatment (adjusted OR 4.1, 95% CI: 0.7-23.9). Stratification according to indication of use showed that current use of alpha-blockers was not associated with hip/femur fracture in men with a diagnosis of benign prostatic hyperplasia (adjusted OR 1.0, 95% CI: 0.4-2.5), but was associated in men who used alpha-blockers for cardiovascular disease (adjusted OR 2.8, 95% CI: 1.4-5.4). CONCLUSION: Current use of alpha-blockers was associated with an increased risk of hip/femur fracture and with the start of a new treatment episode. The effect seemed to be confined to patients who used alpha-blockers for cardiovascular disease. Caution with respect to first-dose effects related to the initiation of a new episode of alpha-blocker treatment is advised. |
| spellingShingle | Souverein, P Van Staa, T Egberts, A De la Rosette, J Cooper, C Leufkens, H Use of alpha-blockers and the risk of hip/femur fractures. |
| title | Use of alpha-blockers and the risk of hip/femur fractures. |
| title_full | Use of alpha-blockers and the risk of hip/femur fractures. |
| title_fullStr | Use of alpha-blockers and the risk of hip/femur fractures. |
| title_full_unstemmed | Use of alpha-blockers and the risk of hip/femur fractures. |
| title_short | Use of alpha-blockers and the risk of hip/femur fractures. |
| title_sort | use of alpha blockers and the risk of hip femur fractures |
| work_keys_str_mv | AT souvereinp useofalphablockersandtheriskofhipfemurfractures AT vanstaat useofalphablockersandtheriskofhipfemurfractures AT egbertsa useofalphablockersandtheriskofhipfemurfractures AT delarosettej useofalphablockersandtheriskofhipfemurfractures AT cooperc useofalphablockersandtheriskofhipfemurfractures AT leufkensh useofalphablockersandtheriskofhipfemurfractures |